Nubeqa Európai Unió - magyar - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - prosztata daganatok, kasztráció-rezisztens - endokrin terápia - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.